NP-MRD: Showing NP-Card for Sepiapterin (NP0000204)

Jump To Section:

Identification Spectra BioTaxonomy ChemoTaxonomy Physical properties Links References XML

Record Information

Version

2.0

Created at

2005-11-16 15:48:42 UTC

Updated at

2021-07-01 14:27:31 UTC

NP-MRD ID

NP0000204

Secondary Accession Numbers

None

Natural Product Identification

Common Name

Sepiapterin

Description

Sepiapterin, also known as 2-amino-6-lactoyl-7,8-dihydropteridin-4(3H)-one, belongs to the class of organic compounds known as pterins and derivatives. These are polycyclic aromatic compounds containing a pterin moiety, which consist of a pteridine ring bearing a ketone and an amine group to form 2-aminopteridin-4(3H)-one. Sepiapterin is also classified as a member of the pteridine class of organic chemicals. It is a yellow fluorescing pigment. Sepiapterin is an intermediate in the salvage pathway of tetrahydrobiopterin (BH(4)). More specifically, sepiapterin can be metabolized into tetrahydrobiopterin via the BH(4) salvage pathway. Tetrahydrobiopterin is an essential cofactor in humans for breakdown of phenylalanine and a catalyst of the metabolism of phenylalanine, tyrosine, and tryptophan to the neurotransmitters dopamine and serotonin. A deficiency of tetrahydrobiopterin can cause toxic buildup of phenylalanine (phenylketonuria) as well as deficiencies of dopamine, norepinephrine, and epinephrine, leading to dystonia and other neurological illnesses. Sepiapterin accumulates in the brain of patients with sepiapterin reductase (SR) deficiency, an inborn error of metabolism. Sepiapterin reductase deficiency is a condition characterized by movement problems, most often a pattern of involuntary, sustained muscle contractions known as dystonia. Other movement problems can include muscle stiffness (spasticity), tremors, problems with coordination and balance (ataxia), and involuntary jerking movements (chorea). People with sepiapterin reductase deficiency can experience episodes called oculogyric crises. These episodes involve abnormal rotation of the eyeballs; extreme irritability and agitation; and pain, muscle spasms, and uncontrolled movements, especially of the head and neck. Movement abnormalities are often worse late in the day. Most affected individuals have delayed development of motor skills such as sitting and crawling, and they typically are not able to walk unassisted. The problems with movement tend to worsen over time. Within humans, sepiapterin participates in a number of enzymatic reactions. In particular, sepiapterin can be converted into 7,8-dihydroneopterin; which is mediated by the enzyme sepiapterin reductase. In addition, sepiapterin can be converted into 7,8-dihydroneopterin through its interaction with the enzyme carbonyl reductase [NADPH] 1.

Structure

MOL 3D MOL SDF 3D SDF PDB 3D PDB SMILES InChI

Serotonin.mol
  Mrv1652305271900292D          

 17 18  0  0  0  0            999 V2000
   -1.6500   -0.7145    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0625    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6500    0.7145    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8250    0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4125    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4125    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8250   -0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4125   -1.4289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4125   -1.4289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8250   -0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4125    1.4289    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6500   -0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0625    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    2.8875    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0625   -1.4289    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6500    0.7145    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8875    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
  1 10  1  0  0  0  0
  5 10  2  0  0  0  0
  4 11  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
 12 15  2  0  0  0  0
 13 16  1  1  0  0  0
  7 12  1  0  0  0  0
  2 17  1  0  0  0  0
M  END
> <DATABASE_ID>
NP0000204

> <DATABASE_NAME>
NP-MRD

> <SMILES>
C[C@H](O)C(=O)C1=NC2=C(NC1)NC(N)=NC2=O

> <INCHI_IDENTIFIER>
InChI=1S/C9H11N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,15H,2H2,1H3,(H4,10,11,13,14,17)/t3-/m0/s1

> <INCHI_KEY>
VPVOXUSPXFPWBN-VKHMYHEASA-N

> <FORMULA>
C9H11N5O3

> <MOLECULAR_WEIGHT>
237.2153

> <EXACT_MASS>
237.086189243

> <JCHEM_ACCEPTOR_COUNT>
8

> <JCHEM_ATOM_COUNT>
28

> <JCHEM_AVERAGE_POLARIZABILITY>
22.440769510601005

> <JCHEM_BIOAVAILABILITY>
1

> <JCHEM_DONOR_COUNT>
4

> <JCHEM_FORMAL_CHARGE>
0

> <JCHEM_GHOSE_FILTER>
0

> <JCHEM_IUPAC>
2-amino-6-[(2S)-2-hydroxypropanoyl]-1,4,7,8-tetrahydropteridin-4-one

> <ALOGPS_LOGP>
-1.09

> <JCHEM_LOGP>
-1.3689492123333329

> <ALOGPS_LOGS>
-2.30

> <JCHEM_MDDR_LIKE_RULE>
0

> <JCHEM_NUMBER_OF_RINGS>
2

> <JCHEM_PHYSIOLOGICAL_CHARGE>
0

> <JCHEM_PKA>
13.787245744179138

> <JCHEM_PKA_STRONGEST_ACIDIC>
9.17814455890009

> <JCHEM_PKA_STRONGEST_BASIC>
-1.309143926918912

> <JCHEM_POLAR_SURFACE_AREA>
129.17

> <JCHEM_REFRACTIVITY>
67.49680000000001

> <JCHEM_ROTATABLE_BOND_COUNT>
2

> <JCHEM_RULE_OF_FIVE>
1

> <ALOGPS_SOLUBILITY>
1.18e+00 g/l

> <JCHEM_TRADITIONAL_IUPAC>
sepiapterin

> <JCHEM_VEBER_RULE>
0

$$$$

HEADER    PROTEIN                                 27-MAY-19   NONE
TITLE     NULL                                                        
COMPND    MOLECULE: Serotonin.mol                                     
SOURCE    NULL                                                        
KEYWDS    NULL                                                        
EXPDTA    NULL                                                        
AUTHOR    Marvin                                                      
REVDAT   1   27-MAY-19         0                                  
HETATM    1  N   UNK     0      -3.080  -1.334   0.000  0.00  0.00           N+0
HETATM    2  C   UNK     0      -3.850   0.000   0.000  0.00  0.00           C+0
HETATM    3  N   UNK     0      -3.080   1.334   0.000  0.00  0.00           N+0
HETATM    4  C   UNK     0      -1.540   1.334   0.000  0.00  0.00           C+0
HETATM    5  C   UNK     0      -0.770   0.000   0.000  0.00  0.00           C+0
HETATM    6  N   UNK     0       0.770   0.000   0.000  0.00  0.00           N+0
HETATM    7  C   UNK     0       1.540  -1.334   0.000  0.00  0.00           C+0
HETATM    8  C   UNK     0       0.770  -2.667   0.000  0.00  0.00           C+0
HETATM    9  N   UNK     0      -0.770  -2.667   0.000  0.00  0.00           N+0
HETATM   10  C   UNK     0      -1.540  -1.334   0.000  0.00  0.00           C+0
HETATM   11  O   UNK     0      -0.770   2.667   0.000  0.00  0.00           O+0
HETATM   12  C   UNK     0       3.080  -1.334   0.000  0.00  0.00           C+0
HETATM   13  C   UNK     0       3.850   0.000   0.000  0.00  0.00           C+0
HETATM   14  C   UNK     0       5.390   0.000   0.000  0.00  0.00           C+0
HETATM   15  O   UNK     0       3.850  -2.667   0.000  0.00  0.00           O+0
HETATM   16  O   UNK     0       3.080   1.334   0.000  0.00  0.00           O+0
HETATM   17  N   UNK     0      -5.390   0.000   0.000  0.00  0.00           N+0
CONECT    1    2   10                                                       
CONECT    2    1    3   17                                                  
CONECT    3    2    4                                                       
CONECT    4    3    5   11                                                  
CONECT    5    4    6   10                                                  
CONECT    6    5    7                                                       
CONECT    7    6    8   12                                                  
CONECT    8    7    9                                                       
CONECT    9    8   10                                                       
CONECT   10    9    1    5                                                  
CONECT   11    4                                                            
CONECT   12   13   15    7                                                  
CONECT   13   12   14   16                                                  
CONECT   14   13                                                            
CONECT   15   12                                                            
CONECT   16   13                                                            
CONECT   17    2                                                            
MASTER        0    0    0    0    0    0    0    0   17    0   36    0
END

COMPND    HMDB0000238
HETATM    1  C1  UNL     1      -4.322  -0.297   0.704  1.00  0.00           C  
HETATM    2  C2  UNL     1      -3.264  -0.498  -0.352  1.00  0.00           C  
HETATM    3  O1  UNL     1      -2.469  -1.579  -0.004  1.00  0.00           O  
HETATM    4  C3  UNL     1      -2.472   0.704  -0.627  1.00  0.00           C  
HETATM    5  O2  UNL     1      -3.035   1.760  -0.952  1.00  0.00           O  
HETATM    6  C4  UNL     1      -1.005   0.667  -0.519  1.00  0.00           C  
HETATM    7  N1  UNL     1      -0.424  -0.439  -0.179  1.00  0.00           N  
HETATM    8  C5  UNL     1       0.973  -0.564  -0.052  1.00  0.00           C  
HETATM    9  C6  UNL     1       1.772   0.528  -0.296  1.00  0.00           C  
HETATM   10  N2  UNL     1       3.123   0.418  -0.177  1.00  0.00           N  
HETATM   11  C7  UNL     1       3.709  -0.730   0.175  1.00  0.00           C  
HETATM   12  N3  UNL     1       5.124  -0.814   0.293  1.00  0.00           N  
HETATM   13  N4  UNL     1       2.919  -1.792   0.412  1.00  0.00           N  
HETATM   14  C8  UNL     1       1.586  -1.746   0.311  1.00  0.00           C  
HETATM   15  O3  UNL     1       0.852  -2.730   0.531  1.00  0.00           O  
HETATM   16  N5  UNL     1       1.185   1.758  -0.671  1.00  0.00           N  
HETATM   17  C9  UNL     1      -0.229   1.885  -0.800  1.00  0.00           C  
HETATM   18  H1  UNL     1      -4.954   0.583   0.480  1.00  0.00           H  
HETATM   19  H2  UNL     1      -5.005  -1.178   0.663  1.00  0.00           H  
HETATM   20  H3  UNL     1      -3.911  -0.269   1.733  1.00  0.00           H  
HETATM   21  H4  UNL     1      -3.809  -0.800  -1.286  1.00  0.00           H  
HETATM   22  H5  UNL     1      -2.116  -1.981  -0.830  1.00  0.00           H  
HETATM   23  H6  UNL     1       3.711   1.266  -0.369  1.00  0.00           H  
HETATM   24  H7  UNL     1       5.693  -1.551  -0.175  1.00  0.00           H  
HETATM   25  H8  UNL     1       5.639  -0.114   0.870  1.00  0.00           H  
HETATM   26  H9  UNL     1       1.845   2.560  -0.846  1.00  0.00           H  
HETATM   27  H10 UNL     1      -0.530   2.214  -1.831  1.00  0.00           H  
HETATM   28  H11 UNL     1      -0.587   2.739  -0.149  1.00  0.00           H  
CONECT    1    2   18   19   20
CONECT    2    3    4   21
CONECT    3   22
CONECT    4    5    5    6
CONECT    6    7    7   17
CONECT    7    8
CONECT    8    9    9   14
CONECT    9   10   16
CONECT   10   11   23
CONECT   11   12   13   13
CONECT   12   24   25
CONECT   13   14
CONECT   14   15   15
CONECT   16   17   26
CONECT   17   27   28
END

View in JSmol

Synonyms

Value	Source
(S)-2-Amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-4(1H)-pteridinone	HMDB
1-(2-Amino-7,8-dihydro-4-hydroxy-6-pteridinyl)-2-hydroxy-1-propanone	HMDB
2-Amino-6-(S)-lactoyl-7,8-dihydro-4(3H)-pteridinone	HMDB
2-Amino-7,8-dihydro-6-[(2S)-2-hydroxy-1-oxopropyl]-4(1H)pteridinone	HMDB
L-Sepiapterin	HMDB
Lopac-S-154	HMDB
Sepiapterine	HMDB
Sepiapterin-C	HMDB
2-Amino-6-(S)-lactoyl-7,8-dihydro-4(3H)- pteridinone	HMDB
Sepia-pterin	HMDB
2-Amino-7,8-dihydro-6-((2S)-2-hydroxy-1-oxopropyl)-4(3H)-pteridinone acid	HMDB

Chemical Formula

C₉H₁₁N₅O₃

Average Mass

237.2153 Da

Monoisotopic Mass

237.08619 Da

IUPAC Name

2-amino-6-[(2S)-2-hydroxypropanoyl]-1,4,7,8-tetrahydropteridin-4-one

Traditional Name

sepiapterin

CAS Registry Number

17094-01-8

SMILES

C[C@H](O)C(=O)C1=NC2=C(NC1)NC(N)=NC2=O

InChI Identifier

InChI=1S/C9H11N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,15H,2H2,1H3,(H4,10,11,13,14,17)/t3-/m0/s1

InChI Key

VPVOXUSPXFPWBN-VKHMYHEASA-N

Experimental Spectra

Spectrum Type	Description	Depositor Email	Depositor Organization	Depositor	Deposition Date	View
1D NMR	¹H NMR Spectrum (1D, 600 MHz, DMSO, simulated)	V.dorna83			2021-09-07	View Spectrum
2D NMR	[¹H, ¹³C]-HSQC NMR Spectrum (2D, 600 MHz, 100%_DMSO, experimental)	Wishart Lab	Wishart Lab	David Wishart	2021-06-20	View Spectrum

Predicted Spectra

Not Available

Chemical Shift Submissions

Spectrum Type	Description	Depositor Email	Depositor Organization	Depositor	Deposition Date	View
1D NMR	¹H NMR Spectrum (1D, 600 MHz, DMSO, simulated)	v.dorna83@yahoo.com	Not Available	Not Available	2021-08-12	View Spectrum

Species

Species of Origin

Species Name	Source	Reference
Anas platyrhynchos	FooDB	FooDB
Anatidae	FooDB	FooDB
Anser anser	FooDB	FooDB
Bison bison	FooDB	FooDB
Bombyx mori	LOTUS Database	35616633
Bos taurus	FooDB	FooDB
Bos taurus X Bison bison	FooDB	FooDB
Bubalus bubalis	FooDB	FooDB
Capra aegagrus hircus	FooDB	FooDB
Cervidae	FooDB	FooDB
Cervus canadensis	FooDB	FooDB
Columba	FooDB	FooDB
Columbidae	FooDB	FooDB
Dromaius novaehollandiae	FooDB	FooDB
Equus caballus	FooDB	FooDB
Gallus gallus	FooDB	FooDB
Lagopus muta	FooDB	FooDB
Leporidae	FooDB	FooDB
Lepus timidus	FooDB	FooDB
Melanitta fusca	FooDB	FooDB
Meleagris gallopavo	FooDB	FooDB
Numida meleagris	FooDB	FooDB
Odocoileus	FooDB	FooDB
Oryctolagus	FooDB	FooDB
Ovis aries	FooDB	FooDB
Phasianidae	FooDB	FooDB
Phasianus colchicus	FooDB	FooDB
Struthio camelus	FooDB	FooDB
Sus scrofa	FooDB	FooDB
Sus scrofa domestica	FooDB	FooDB

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as pterins and derivatives. These are polycyclic aromatic compounds containing a pterin moiety, which consist of a pteridine ring bearing a ketone and an amine group to form 2-aminopteridin-4(3H)-one.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Pteridines and derivatives

Sub Class

Pterins and derivatives

Direct Parent

Pterins and derivatives

Alternative Parents

Substituents

Pterin
Aminopyrimidine
Pyrimidone
Secondary aliphatic/aromatic amine
Acyloin
Pyrimidine
Alpha-hydroxy ketone
Heteroaromatic compound
Vinylogous amide
Secondary alcohol
Ketimine
Ketone
Propargyl-type 1,3-dipolar organic compound
Secondary amine
Azacycle
Organic 1,3-dipolar compound
Alcohol
Primary amine
Organooxygen compound
Organonitrogen compound
Organopnictogen compound
Organic oxide
Imine
Carbonyl group
Organic oxygen compound
Amine
Hydrocarbon derivative
Organic nitrogen compound
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Physical Properties

State

Solid

Experimental Properties

Property	Value	Reference
Melting Point	Not Available	Not Available
Boiling Point	Not Available	Not Available
Water Solubility	Not Available	Not Available
LogP	Not Available	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	1.18 g/L	ALOGPS
logP	-1.1	ALOGPS
logP	-1.4	ChemAxon
logS	-2.3	ALOGPS
pKa (Strongest Acidic)	9.18	ChemAxon
pKa (Strongest Basic)	-1.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	129.17 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	67.5 m³·mol⁻¹	ChemAxon
Polarizability	22.44 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

External Links

HMDB ID

HMDB0000238

DrugBank ID

Not Available

Phenol Explorer Compound ID

Not Available

FoodDB ID

FDB021914

KNApSAcK ID

Not Available

Chemspider ID

58746

KEGG Compound ID

C00835

BioCyc ID

Not Available

BiGG ID

Not Available

Wikipedia Link

Sepiapterin

METLIN ID

5244

PubChem Compound

65253

PDB ID

Not Available

ChEBI ID

804632

Good Scents ID

Not Available

References

General References

Zorzi G, Redweik U, Trippe H, Penzien JM, Thony B, Blau N: Detection of sepiapterin in CSF of patients with sepiapterin reductase deficiency. Mol Genet Metab. 2002 Feb;75(2):174-7. [PubMed:11855937 ]
Keller M, Brennenstuhl H, Kuseyri Hubschmann O, Manti F, Julia Palacios NA, Friedman J, Yildiz Y, Koht JA, Wong SN, Zafeiriou DI, Lopez-Laso E, Pons R, Kulhanek J, Jeltsch K, Serrano-Lomelin J, Garbade SF, Opladen T, Goez H, Burlina A, Cortes-Saladelafont E, Fernandez Ramos JA, Garcia-Cazorla A, Hoffmann GF, Kiat Hong ST, Honzik T, Kavecan I, Kurian MA, Leuzzi V, Lucke T, Manzoni F, Mastrangelo M, Mercimek-Andrews S, Mir P, Oppeboen M, Pearson TS, Sivri HS, Steel D, Stevanovic G, Fung CW: Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry. J Inherit Metab Dis. 2021 Jul 9. doi: 10.1002/jimd.12416. [PubMed:34245036 ]
Abell TL, Garcia LM, Wiener GJ, Wo JM, Bulat RS, Smith N: Effect of Oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: A randomized, placebo-controlled, Phase 2 trial. J Diabetes Complications. 2021 Sep;35(9):107961. doi: 10.1016/j.jdiacomp.2021.107961. Epub 2021 Jun 17. [PubMed:34176722 ]
Bozaci AE, Er E, Yazici H, Canda E, Kalkan Ucar S, Guvenc Saka M, Eraslan C, Onay H, Habif S, Thony B, Coker M: Tetrahydrobiopterin deficiencies: Lesson from clinical experience. JIMD Rep. 2021 Feb 1;59(1):42-51. doi: 10.1002/jmd2.12199. eCollection 2021 May. [PubMed:33977029 ]
Obeng S, Hiranita T, Leon F, McMahon LR, McCurdy CR: Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. J Med Chem. 2021 May 27;64(10):6523-6548. doi: 10.1021/acs.jmedchem.1c00028. Epub 2021 May 6. [PubMed:33956427 ]
Furukawa Y, Tomizawa Y, Nakahara T: Neurometabolic causes of dystonia: Sepiapterin reductase-deficient dopamine- and serotonin-responsive dystonia-plus syndrome. J Neurol Sci. 2021 Jun 15;425:117468. doi: 10.1016/j.jns.2021.117468. Epub 2021 Apr 21. [PubMed:33926741 ]
Himmelreich N, Blau N, Thony B: Molecular and metabolic bases of tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2021 Jun;133(2):123-136. doi: 10.1016/j.ymgme.2021.04.003. Epub 2021 Apr 19. [PubMed:33903016 ]
Phua CS, Kumar KR, Levy S: Reply to: Neurometabolic causes of dystonia: Sepiapterin reductase-deficient dopamine- and serotonin-responsive dystonia-plus syndrome. J Neurol Sci. 2021 Jun 15;425:117469. doi: 10.1016/j.jns.2021.117469. Epub 2021 Apr 21. [PubMed:33902913 ]
Rabender CS, Mezzaroma E, Yakovlev VA, Mauro AG, Bonaventura A, Abbate A, Mikkelsen RB: Mitigation of Radiation-Induced Lung and Heart Injuries in Mice by Oral Sepiapterin after Irradiation. Radiat Res. 2021 May 1;195(5):463-473. doi: 10.1667/RADE-20-00249.1. [PubMed:33822229 ]
Ranjpour M, Wajid S, Jain SK: Elevated expression of sepiapterin reductase, regulator of G protein signaling 1, hypothetical protein CXorf58 homolog, and zinc finger and BTB domain-containing protein 21 isoform X2 is associated with progression of hepatocellular carcinoma. Protoplasma. 2021 Mar 8. pii: 10.1007/s00709-021-01632-2. doi: 10.1007/s00709-021-01632-2. [PubMed:33683453 ]
Lindsay A, Kemp B, Larson AA, Baumann CW, McCourt PM, Holm J, Karachunski P, Lowe DA, Ervasti JM: Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans. Acta Physiol (Oxf). 2021 Apr;231(4):e13627. doi: 10.1111/apha.13627. Epub 2021 Mar 8. [PubMed:33580591 ]
Cherian A, Paramasivan NK, Divya KP: Dopa-responsive dystonia, DRD-plus and DRD look-alike: a pragmatic review. Acta Neurol Belg. 2021 Jun;121(3):613-623. doi: 10.1007/s13760-020-01574-1. Epub 2021 Jan 16. [PubMed:33453040 ]
Zhang X, Chen Y, Wang K, Tang J, Chen Y, Jin G, Liu X: The knockdown of the sepiapterin reductase gene suppresses the proliferation of breast cancer by inducing ROS-mediated apoptosis. Int J Clin Exp Pathol. 2020 Sep 1;13(9):2228-2239. eCollection 2020. [PubMed:33042327 ]
Wu Y, Chen P, Sun L, Yuan S, Cheng Z, Lu L, Du H, Zhan M: Sepiapterin reductase: Characteristics and role in diseases. J Cell Mol Med. 2020 Sep;24(17):9495-9506. doi: 10.1111/jcmm.15608. Epub 2020 Jul 30. [PubMed:32734666 ]
Oates JC, Ramakrishnan V, Nietert PJ, Spence JD, Fleury TW, Markiewicz M, Russell DL, Lopes-Virella MF: ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. Trans Am Clin Climatol Assoc. 2020;131:157-177. [PubMed:32675856 ]
Soares AG, Muscara MN, Costa SKP: Molecular mechanism and health effects of 1,2-Naphtoquinone. EXCLI J. 2020 Jun 3;19:707-717. doi: 10.17179/excli2020-1210. eCollection 2020. [PubMed:32636724 ]
Mainka T, Hoffmann J, Kuhn AA, Biskup S, Ganos C: Teaching Video NeuroImages: Paroxysmal hyperkinesia with diurnal fluctuations due to sepiapterin-reductase deficiency. Neurology. 2020 Jul 21;95(3):e332-e334. doi: 10.1212/WNL.0000000000009901. Epub 2020 Jun 26. [PubMed:32591469 ]

Showing NP-Card for Sepiapterin (NP0000204)

MOL for NP0000204 (Sepiapterin)

3D MOL for NP0000204 (Sepiapterin)

3D SDF for NP0000204 (Sepiapterin)

3D-SDF for NP0000204 (Sepiapterin)

PDB for NP0000204 (Sepiapterin)

3D PDB for NP0000204 (Sepiapterin)

SMILES for NP0000204 (Sepiapterin)

INCHI for NP0000204 (Sepiapterin)

Structure for NP0000204 (Sepiapterin)

3D Structure for NP0000204 (Sepiapterin)